NCT02080026View on ClinicalTrials.gov

Target Antigens Induced by Plasmodium Falciparum Sporozoite Immunization Under Chemoprophylaxis

NACompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Malaria
Interventions
BIOLOGICAL

CPS-immunization

Subjects will receive four 'immunizations' with bites from 15 Plasmodium infected mosquitoes during each immunization, while taking chloroquine prophylaxis.

BIOLOGICAL

Controlled Human Malaria Infection

Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum, NF54 strain.

DRUG

chloroquine

Registered for prophylaxis against infection with Plasmodium falciparum and the treatment of acute infections.

DRUG

atovaquone/proguanil

"Registered for use as an antimalarial agent for the treatment of acute infections with Plasmodium falciparum.~One tablet contains: atovaquone 250 mg, proguanil(hydrochloride) 100 mg"

Trial Locations (1)

6525 GA

Radboud university medical center, Nijmegen

All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

lead

Radboud University Medical Center

OTHER

NCT02080026 - Target Antigens Induced by Plasmodium Falciparum Sporozoite Immunization Under Chemoprophylaxis | Biotech Hunter | Biotech Hunter